Literature DB >> 10438153

Effects of glucocorticoids on the trabecular meshwork: towards a better understanding of glaucoma.

R J Wordinger1, A F Clark.   

Abstract

Glucocorticoid effects on the human trabecular meshwork can be used as a model system in which to study glaucomatous damage to the trabecular meshwork. One of the most important risk factors for glaucoma is an elevated intraocular pressure. The administration of glucocorticoids also can cause elevated intraocular pressure in some individuals. In addition, there is suggestive evidence linking glucocorticoids with the development of glaucoma. Glucocorticoids cause multiple effects on the human trabecular meshwork including changes in extracellular matrix metabolism, organisation of the cytoskeleton, and changes in gene expression and cell function. New discoveries on the molecular mechanisms of glucocorticoid receptor action provide new opportunities to study the possible role of this receptor in the development of glaucoma. For example, alternate spliced forms of the glucocorticoid receptor, glucocorticoid receptor response element half-sites, numerous modulatory factors, and direct effects of nuclear transcription factors have been recently described. Other recent information has shown that the new glaucoma gene (GLC1A/myocilin) is induced in the human trabecular meshwork by glucocorticoids. Although the exact function of myocilin is currently unknown, it offers the opportunity to dissect the molecular pathways regulating aqueous humor outflow. Future challenges include determining (1) which glucocorticoid effects in the human trabecular meshwork are responsible for elevated intraocular pressure; and (2) the significance of these findings to the development of glaucoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438153     DOI: 10.1016/s1350-9462(98)00035-4

Source DB:  PubMed          Journal:  Prog Retin Eye Res        ISSN: 1350-9462            Impact factor:   21.198


  74 in total

1.  VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis.

Authors:  Blythe C Dillingham; Susan M Knoblach; Gina M Many; Brennan T Harmon; Amanda M Mullen; Christopher R Heier; Luca Bello; John M McCall; Eric P Hoffman; Edward M Connor; Kanneboyina Nagaraju; Erica K M Reeves; Jesse M Damsker
Journal:  Cell Mol Neurobiol       Date:  2014-11-13       Impact factor: 5.046

2.  Dexamethasone-associated cross-linked actin network formation in human trabecular meshwork cells involves β3 integrin signaling.

Authors:  Mark S Filla; Marie K Schwinn; Amanda K Nosie; Ross W Clark; Donna M Peters
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-05       Impact factor: 4.799

3.  Beta1 and beta3 integrins cooperate to induce syndecan-4-containing cross-linked actin networks in human trabecular meshwork cells.

Authors:  Mark S Filla; Anne Woods; Paul L Kaufman; Donna M Peters
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

4.  Irreversible visual loss secondary to excessive topical steroid use in eczema.

Authors:  Charles Lim Fat; Thorfinn Leslie
Journal:  Br J Gen Pract       Date:  2011-09       Impact factor: 5.386

Review 5.  Glaucoma-associated myocilin: a better understanding but much more to learn.

Authors:  Zachary T Resch; Michael P Fautsch
Journal:  Exp Eye Res       Date:  2008-08-29       Impact factor: 3.467

Review 6.  Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.

Authors:  M Elizabeth Fini; Stephen G Schwartz; Xiaoyi Gao; Shinwu Jeong; Nitin Patel; Tatsuo Itakura; Marianne O Price; Francis W Price; Rohit Varma; W Daniel Stamer
Journal:  Prog Retin Eye Res       Date:  2016-09-22       Impact factor: 21.198

7.  Triamcinolone acetonide decreases outflow facility in C57BL/6 mouse eyes.

Authors:  Sandeep Kumar; Shaily Shah; Emily Rose Deutsch; Hai Michael Tang; John Danias
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

8.  Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus.

Authors:  Rosana Gerometta; Maria-Grazia Spiga; Teresa Borrás; Oscar A Candia
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

9.  Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma.

Authors:  Maria-Grazia Spiga; Teresa Borrás
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

10.  Bioengineered glaucomatous 3D human trabecular meshwork as an in vitro disease model.

Authors:  Karen Y Torrejon; Ellen L Papke; Justin R Halman; Judith Stolwijk; Cula N Dautriche; Magnus Bergkvist; John Danias; Susan T Sharfstein; Yubing Xie
Journal:  Biotechnol Bioeng       Date:  2015-12-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.